Ix Biopharma Ltd. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies using its proprietary sublingual drug delivery system, WaferiX. This platform is designed to enhance the absorption of drugs through the mucosal lining for rapid therapeutic effects, bypassing traditional oral administration's digestive limitations. Ix Biopharma Ltd. plays a pivotal role in the pharmaceutical sector by addressing unmet medical needs across various areas, such as pain management, men’s health, and mental health disorders. The company's products are delivered via thin, absorbable wafers, offering an alternative to conventional tablets or capsules. Headquartered in Singapore, Ix Biopharma Ltd. primarily targets global markets seeking advanced drug delivery solutions. Its deep focus on research and development and strategic partnerships aim to expand its product pipeline, increasing its influence in the healthcare industry. By leveraging innovative delivery mechanisms, Ix Biopharma Ltd. contributes to improving patient outcomes and broadening the accessibility of essential medicines.